# Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).

> **NCT06754384** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 552 (actual)

## Conditions studied

- Hand, Foot, and Mouth Disease (HFMD)
- Herpangina

## Interventions

- **BIOLOGICAL:** Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)
- **BIOLOGICAL:** Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
- **BIOLOGICAL:** High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
- **BIOLOGICAL:** EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）
- **BIOLOGICAL:** placebo (for ages 6-12 years)

## Key facts

- **NCT ID:** NCT06754384
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-15
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-02-10
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754384, "Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06754384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*